{"entity":{"id":"paper-duo-e-jco-2023","kind":"paper","name":"DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer","aka":[],"tldr":"Adding durvalumab to first-line chemotherapy delayed progression in advanced endometrial cancer, and adding the PARP inhibitor olaparib to durvalumab maintenance helped further in mismatch repair-proficient tumours.","summary":"Phase 3 trial of 718 patients with newly diagnosed advanced or recurrent endometrial cancer randomised to carboplatin-paclitaxel alone, with durvalumab followed by durvalumab maintenance, or with durvalumab followed by durvalumab plus olaparib maintenance.\n\nProgression-free survival hazard ratios were 0.71 for durvalumab and 0.55 for durvalumab plus olaparib versus control; in mismatch repair-deficient disease both immunotherapy arms performed similarly (hazard ratio about 0.42), whereas olaparib added benefit in proficient disease (0.57 versus 0.77).","asOf":"2026-09-17","links":[{"label":"J Clin Oncol 2024","url":"https://doi.org/10.1200/JCO.23.02132"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/37864337/"}],"tags":[],"related":[],"cancers":["advanced-recurrent-endometrial-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["carboplatin","durvalumab","olaparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["duo-e"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2024,"doi":"10.1200/JCO.23.02132","pmid":"37864337","authors":"Westin SN, Moore K, Chon HS, et al.","paperType":"rct","findings":["Progression-free survival hazard ratio 0.71 (durvalumab) and 0.55 (durvalumab plus olaparib).","Mismatch repair-proficient: hazard ratio 0.77 vs 0.57 with olaparib added."],"whatItMeans":"Durvalumab-based chemo-immunotherapy is a third first-line option with RUBY and NRG-GY018, and durvalumab plus olaparib maintenance is approved for mismatch repair-proficient disease in some regions.","caveats":["The contribution of olaparib in proficient disease may be concentrated in p53-abnormal tumours; overall survival immature.","Anaemia and neutropenia increased with olaparib."],"changedPractice":true,"participants":718},"route":"/key-papers/paper-duo-e-jco-2023/","neighbours":{"cancer":[{"id":"advanced-recurrent-endometrial-cancer","kind":"cancer","name":"Advanced or recurrent endometrial cancer","route":"/cancers/advanced-recurrent-endometrial-cancer/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"trial":[{"id":"duo-e","kind":"trial","name":"DUO-E / GOG-3041 / ENGOT-EN10","route":"/trials/duo-e/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}